Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.
Peeters, M Price, T Cervantes, A Sobrero, A Ducreux, M Hotko, Y André, T Chan, E Lordick, F Punt, C
Peeters, M
Price, T
Cervantes, A
Sobrero, A
Ducreux, M
Hotko, Y
André, T
Chan, E
Lordick, F
Punt, C
Citations
Altmetric:
Abstract
The study 20050181 demonstrated significant improvements in progression-free survival (PFS), objective response, and a nonsignificant trend toward increased overall survival (OS) with panitumumab-FOLFIRI versus FOLFIRI alone for second-line wild-type (WT) KRAS metastatic colorectal cancer (mCRC). Updated long-term data from a prespecified descriptive analysis are reported.
Description
Date
2014-01
Publisher
Collections
Keywords
Type
Article
Citation
Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer. 2014, 25 (1):107-16 Ann Oncol